stockrow
Monday 9 November 2026
Export PLX’s income statement to Excel — free account
Protalix BioTherapeutics, Inc.
PLXProtalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.
- Revenue
- +27.1%
- EPS
- +2,281.0%
- Free cash flow
- −94.1%
Quarter to June 2026, against a year earlier
2.54
0.03
+1.20%
Follow PLX
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 4 | 3 | 4 | 2 | 3 | 6 | 5 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00 | 47.00 | 0.00 |
P/S ratio |
4.57 | 4.32 | 1.34 | 0.89 | 1.68 | 0.96 | 1.39 | 1.88 | 2.55 | 2.68 |
Altman Z-Score |
(4.46) | (5.85) | (7.09) | (10.04) | (5.98) | (6.78) | (8.83) | (3.38) | (3.04) | (3.05) |
Altman Z″-Score (non-manufacturers) |
(10.80) | (13.26) | (16.85) | (27.81) | (19.67) | (16.00) | (23.05) | (11.31) | (11.86) | (11.01) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.44 | 0.00 |
Beneish M-Score |
— | (6.98) | (3.03) | (0.43) | (1.63) | (2.07) | (1.25) | (1.64) | (3.07) | (0.15) |
P/Operating CF |
(5.73) | 5.17 | (11.43) | (13.20) | (14.01) | (7.20) | (25.43) | 34.18 | 34.17 | 69.65 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.66 | 3.16 | 2.93 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.66 | 3.16 | 2.93 |
EV/Sales |
(0.20) | 4.08 | 1.63 | 1.50 | 1.14 | 0.67 | 1.52 | 1.50 | 2.28 | 2.48 |
EV/EBITDA |
0.06 | 0.00 | 0.00 | 0.00 | 9.59 | 0.00 | 0.00 | 8.26 | 23.30 | 0.00 |
EV/Operating CF |
0.06 | (8.61) | (7.22) | (4.23) | (2.75) | (2.48) | (2.90) | (74.69) | 14.03 | (10.88) |
EV/FCF |
0.06 | (7.85) | (6.63) | (4.09) | (2.68) | (2.18) | (2.83) | (39.90) | 16.45 | (9.58) |
Quick Ratio |
1.01 | 2.32 | 1.68 | 0.56 | 0.47 | 1.28 | 0.83 | 1.09 | 1.47 | 1.50 |
Current Ratio |
1.09 | 2.75 | 2.09 | 0.81 | 0.64 | 1.86 | 1.38 | 1.54 | 2.34 | 2.51 |
Net Debt/EBITDA |
1.44 | 0.16 | (0.68) | (5.43) | (4.55) | 0.67 | (0.52) | (3.74) | (6.67) | 7.68 |
Debt/Assets |
23.52% | 64.07% | 78.46% | 112.26% | 6.58% | 37.86% | 50.53% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.94) | (1.57) | (0.91) | (0.72) | (0.17) | (4.62) | (2.65) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.10 | 0.27 | 0.51 | 1.03 | 1.11 | 0.54 | 0.74 | 0.93 | 0.68 | 0.68 |
Operating CF/Net income |
1.09 | 0.12 | 0.29 | 1.06 | 4.00 | 0.37 | 1.67 | (0.16) | 2.96 | 1.82 |
Capex/Depreciation |
(0.32) | (0.23) | (0.16) | (0.14) | (0.14) | (0.37) | (0.45) | (0.79) | (0.98) | (1.12) |
| (6,411.57%) | 423.40% | 64.26% | 29.67% | 13.40% | 166.79% | 179.02% | 72.50% | 7.64% | (14.44%) | |
| (32.72%) | (108.04%) | (39.68%) | (34.31%) | (11.51%) | (38.96%) | (23.06%) | 11.86% | 3.71% | (8.48%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 29.21% | (19.92%) |
Return on Tangible Assets |
(204.52%) | (175.39%) | (77.77%) | 754.27% | 25.18% | (82.45%) | (87.79%) | 28.30% | 7.51% | (14.66%) |
Average Days of Receivables |
132.57 | 29.80 | 50.41 | 31.37 | 11.61 | 32.76 | 35.14 | 29.38 | 19.88 | 61.17 |
Research and Development Expense of Revenue |
267.51% | 136.80% | 97.34% | 81.58% | 60.68% | 77.53% | 61.61% | 26.10% | 24.29% | 37.10% |
Selling, General and Administrative Expense of Revenue |
101.71% | 54.70% | 31.88% | 18.10% | 17.72% | 33.19% | 24.58% | 22.84% | 22.83% | 22.15% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10.74% | 1.60% | 1.50% | 1.53% | 4.97% | 6.19% | 4.38% | 5.26% | 6.09% | 4.35% |
Graham Net Nets |
(0.48) | (0.43) | (1.33) | (1.71) | (0.37) | (0.49) | (0.32) | 0.16 | 0.22 | 0.23 |
Graham Number |
8.03 | 18.36 | 12.39 | 11.22 | 1.71 | 1.38 | 1.22 | 1.21 | 0.73 | 0.00 |
Earnings Yield |
(70.26%) | (96.03%) | (61.09%) | (35.99%) | (3.86%) | (74.70%) | (21.90%) | 7.14% | 2.13% | (4.88%) |
Free Cash Flow Yield |
(78.26%) | (12.05%) | (18.42%) | (41.06%) | (25.29%) | (31.91%) | (38.59%) | (2.01%) | 5.42% | (9.64%) |
Revenue per Share |
0.91 | 1.61 | 2.33 | 3.69 | 2.16 | 0.87 | 0.98 | 0.97 | 0.74 | 0.67 |
Operating CF per Share |
(3.17) | (0.76) | (0.53) | (1.30) | (0.90) | (0.23) | (0.52) | (0.02) | 0.12 | (0.15) |
Capex per Share |
(0.08) | (0.07) | (0.05) | (0.04) | (0.02) | (0.03) | (0.01) | (0.02) | (0.02) | (0.02) |
Free Cash Flow per Share |
(3.25) | (0.84) | (0.57) | (1.35) | (0.92) | (0.26) | (0.53) | (0.04) | 0.10 | (0.17) |
Cash per Share |
6.24 | 3.90 | 2.57 | 1.20 | 1.32 | 0.88 | 0.46 | 0.66 | 0.48 | 0.39 |
Shareholders Equity per Share |
(0.98) | (2.25) | (3.59) | (4.74) | (0.93) | (0.14) | (0.22) | 0.50 | 0.60 | 0.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.98) | (2.25) | (3.59) | (4.74) | (0.93) | (0.14) | (0.22) | 0.50 | 0.60 | 0.61 |
Free Cash Flow |
(32.93) | (10.96) | (8.43) | (19.98) | (26.76) | (11.69) | (25.63) | (2.47) | 7.40 | (13.63) |
Working Capital |
5.66 | 39.90 | 27.63 | (7.70) | (30.75) | 28.49 | 12.45 | 24.40 | 34.46 | 40.16 |
Capital Expenditures |
(0.83) | (0.97) | (0.69) | (0.63) | (0.65) | (1.41) | (0.63) | (1.15) | (1.28) | (1.64) |
Net Current Asset Value |
(20.34) | (39.02) | (61.03) | (83.23) | (39.25) | (18.03) | (21.55) | 19.07 | 29.87 | 32.56 |
EV/EBIT |
0.06 | 0.00 | 0.00 | 0.00 | 26.47 | 0.00 | 0.00 | 9.41 | 31.06 | 0.00 |
Capex to Sales |
0.09 | 0.05 | 0.02 | 0.01 | 0.01 | 0.04 | 0.01 | 0.02 | 0.02 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 39.04 | 0.00 | 0.00 | 11.75 | 34.81 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.29 | 0.55 | 0.67 | 0.87 | 0.98 | 0.76 | 0.30 | 0.29 | 0.28 | 0.30 |
Cash ROIC |
(45.31%) | (16.13%) | (25.62%) | 1,270.50% | (167.52%) | (19.22%) | (64.51%) | (3.16%) | 9.48% | (17.21%) |
Accounts Receivable Turnover |
3.39 | 8.33 | 10.62 | 11.60 | 18.78 | 14.09 | 11.87 | 13.29 | 13.05 | 8.98 |
Accounts Payable Turnover |
0.81 | 1.08 | 0.58 | 0.64 | 0.55 | 0.73 | 0.94 | 1.09 | 1.01 | 1.10 |
Inventory Turnover |
1.53 | 2.33 | 1.13 | 1.30 | 1.02 | 1.05 | 1.13 | 1.28 | 1.21 | 1.15 |
Average Days of Payables |
499.95 | 403.34 | 607.61 | 616.43 | 709.89 | 522.84 | 337.82 | 379.10 | 362.03 | 339.86 |
Days of Inventory on Hand |
227.96 | 187.71 | 336.24 | 273.21 | 439.15 | 400.83 | 313.06 | 302.47 | 318.83 | 347.91 |
Average Receivables |
2.72 | 2.53 | 3.23 | 4.71 | 3.35 | 2.72 | 4.01 | 4.93 | 4.09 | 5.87 |
Average Payables |
10.33 | 14.17 | 16.16 | 16.94 | 19.77 | 22.28 | 20.78 | 21.00 | 24.00 | 24.63 |
Average Inventory |
5.51 | 6.54 | 8.20 | 8.36 | 10.62 | 15.52 | 17.38 | 17.92 | 20.14 | 23.49 |
Average Assets |
89.75 | 77.23 | 66.67 | 53.26 | 56.66 | 70.80 | 64.73 | 70.11 | 78.93 | 77.88 |
Average Common Equity |
0.46 | (19.71) | (41.17) | (61.60) | (48.68) | (16.54) | (8.34) | 11.46 | 38.39 | 45.72 |
Columns are period end dates